- Prostrate cancer:
- Metastatic: PO 50mg OD
- Use with LHRH analog
- Metastatic: PO 50mg OD
-
- Non-metastatic: PO 150mg OD
- Used as a monotherapy
- Non-metastatic: PO 150mg OD
Tablet:
- 50mg
- 150mg
Taken without regards to food
Nonsteroidal antiandrogen
It competitively binds androgen receptors and inhibits testosterone stimulation of cell growth in prostate cancer
- Hot flashes
- Pain
- Asthenia
- Constipation
- Infection
- Nausea
- Peripheral edema
- Dyspnea
- Nocturia
- Hematuria
- Anemia
- Dizziness
- Gynecomastia
- Rash
- Paresthesia
- URI
- Hypertension
- Headache
- Insomnia
- Elevated ALT/AST
- Photosensitivity
- Hypersensitivity to components
- Female patients
- Pregnancy
- Cisapride
- Flibanserin
- Lomitapide
- Lonafarnib
Drug Status
| Availability | Prescription only |
| Pregnancy | Category X |
| Breastfeeding | Contraindicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Bicatero | 50mg | Tablet | 10’s | Hetero Labs | Unisel Ltd |
| Bypro | 50mg | Tablet | 30’s | Fresenius Kabi Oncology | Nairobi Enterprises |
| Calutami | 50mg | Tablet | 28’s | Proline Healthcare | Proline Healthcare |
| Casodex | 50mg | Tablet | 28’s | AstraZeneca | AstraZeneca |
| Casodex | 150mg | Tablet | 28’s | AstraZeneca | AstraZeneca |
| Prostaglob | 50mg | Tablet | 30’S | Globela Pharma | Globela Pharma |